Colorectal Cancer, Mantle Cell Lymphoma, Advanced Cancer
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
The main purpose of this study is to evaluate the safety of ramucirumab (LY3009806) in combination with other targeted agents in participants with advanced cancers.
The results of this study are not yet available.
The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Study Arm 1 Participants must have advanced or metastatic colorectal cancer confirmed by histology
- Study Arm 1 Participants must have received prior second-line treatment with oxaliplatin and/or irinotecan, and there are no other licensed/standard-of-care therapies are available. If the participant has RAS wild type colorectal cancer, he or she also must have received prior treatment with an epidermal growth factor receptor monoclonal antibody
- Study Arm 2 Participants must have mantle cell lymphoma (MCL) confirmed by pathology
- Study Arm 2 Participants must have MCL that relapsed after or is refractory to (a) first-line combination chemotherapy with or without stem cell transplant and (b) at least 1 other locally available therapy
- Study Arm 2 Participants must provide a newly obtained tumor tissue sample
- Participants must have discontinued all previous treatments for cancer and recovered from the acute effects of therapy
- Participants must agree to the use an effective method of birth control during the study and for at least 3 months post last dose of study drug. Women of child-bearing potential must have negative pregnancy tests before the start of the study and during each treatment cycle
- Participants must not have prior or concurrent cancers, inclusive of blood, primary brain tumor, sarcoma, and other solid tumors, unless in complete remission with no therapy for a minimum of 5 years
- Participants must not have active gastrointestinal (GI) disease characterized by inflammatory bowel disease, malabsorption syndrome, or frequent diarrhea
- Participants must not have experienced a blood clot in the past 6 months